Distinct mechanisms of dysfunctional antigen‐presenting DCs and monocytes by single‐cell sequencing in multiple myeloma

Jinxing Jiang,Jing Xiang,Mengping Chen,Yike Wan,Lu Zhong,Xiaofeng Han,Xiaotong Chen,Junying Wang,Fei Xiao,Jia Liu,Hua Li,Honghui Huang,Jian Hou
DOI: https://doi.org/10.1111/cas.15800
IF: 5.7
2023-04-03
Cancer Science
Abstract:Multiple myeloma (MM) is an incurable plasma cell malignancy with the hallmark of immunodeficiency, including dysfunction of T cells, NK cells and antigen presentation cells (APC). Dysfunctional APCs have been reported to play a key role in promoting MM progression. However, the molecular mechanisms remain elusive. Here, single‐cell transcriptome analysis of dendritic cells (DC) and monocytes from 10 MM patients and 3 healthy volunteers was performed. Both DCs and monocytes were divided into 5 distinct clusters respectively. Among them, monocyte‐derived DC (mono‐DC) was shown to develop from intermediate monocyte (IM) via trajectory analysis. Functional analysis showed that compared with healthy controls, conventional DC2 (cDC2), mono‐DC and IM of MM patients exhibited impaired antigen processing and presentation capacity. Moreover, reduced regulon activity of interferon regulatory factor 1 (IRF1) was found in cDC2, mono‐DC and IM of MM patients according to SCENIC analysis, while the downstream mechanisms were distinct. Specifically in MM patients, cathepsin S (CTSS) was remarkably downregulated in cDC2, MHC class II transactivator (CIITA) was significantly decreased in IM, meanwhile both CTSS and CIITA were downregulated in mono‐DC based on DEG analysis. In vitro study validated that knockdown of Irf1 downregulated Ctss and Ciita respectively in mouse DC cell line DC2.4 and mouse monocyte/macrophage cell line RAW264.7, which ultimately inhibited proliferation of CD4+ T cells after being cocultured with DC2.4 or RAW264.7 cells. The current study unveils the distinct mechanisms of cDC2, IM and mono‐DC function impairment in MM, offering a new insight into the pathogenesis of immunodeficiency.
oncology
What problem does this paper attempt to address?